Acromegaly — Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Citation(s)
Phase IIIb, Multicentre, Open-label, Single-arm, Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 mg Administered Every 28 Days as Primary Medical Treatment in Acromegalic Patients With Macroadenoma